Showing results (161-170 of 6,006) with videos related to

Sort By:
Pageof 601
Molecular Cancer Therapeutics|February 26, 2021
Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum StressKorie A Grayson, Jacob M Hope, Wenjun Wang, et al.
Molecular Cancer Therapeutics|February 5, 2017
Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung CancerHatim Husain, Michael Scur, Ayesha Murtuza, et al.
Molecular Cancer Therapeutics|March 5, 2017
G-1 Inhibits Breast Cancer Cell Growth via Targeting Colchicine-Binding Site of Tubulin to Interfere with Microtubule AssemblyXiangmin Lv, Chunbo He, Cong Huang, et al.
Molecular Cancer Therapeutics|March 16, 2017
Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation InhibitorCasey G Langdon, James T Platt, Robert E Means, et al.
Molecular Cancer Therapeutics|March 16, 2017
Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 NanoparticlesNicolas Floc'h, Susan Ashton, Paula Taylor, et al.
Molecular Cancer Therapeutics|March 16, 2017
Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung CancerJörg Willuda, Lars Linden, Hans-Georg Lerchen, et al.
Molecular Cancer Therapeutics|August 15, 2019
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular CancerAndreas Weiss, Flavia Adler, Alexandra Buhles, et al.
Molecular Cancer Therapeutics|August 28, 2020
Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 InductionIvana Spasevska, Eva Laure Matera, Kamel Chettab, et al.
Molecular Cancer Therapeutics|August 28, 2020
Targeted Radionuclide Therapy in Patient-Derived Xenografts Using 177Lu-EB-RGDLiang Zhao, Haojun Chen, Zhide Guo, et al.
Molecular Cancer Therapeutics|August 28, 2020
Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 AgonismMarije B Overdijk, Kristin Strumane, Frank J Beurskens, et al.
Pageof 601